treptococcus pneumoniae is the leading cause of bacterial infections in children, including meningitis, bacteremia, bacteremic pneumonia, empyema, and mucosal infections such as otitis media and nonbacteremic pneumonia. After the implementation of pneumococcal conjugate vaccines (PCVs), worldwide, the burden of invasive pneumococcal diseases (IPDs) and non-invasive pneumococcal diseases due to vaccine serotypes (VTs) greatly decreased in children. 1 However, since 2015, several European countries have reported an increased incidence of IPDs due to non-vaccine serotypes (NVTs), which seemed variable across countries in terms of magnitude, serotypes involved, and clinical entities. 1-4 This led to questions regarding the long-term benefit of PCVs. This commentary presents an overview of serotype replacement in pneumococcal carriage and diseases in Europe, with a focus on IPDs. The aim is to raise awareness among pediatricians and healthcare professionals of the potential factors involved in the phenomenon of serotype replacement diversity after PCV implementation. In addition, we analyze the potential factors involved in this phenomenon. We selected European observational studies assessing the impact of PCV10 and PCV13 beyond 5 years after their implementation at the population level in children. We reviewed the literature in MEDLINE via PubMed, with no time or language restriction (last search June 30, 2019). The search algorithm was based on a combination of terms related to "13-or 10-valent PCV," "pneumococcal diseases or pneumococcal carriage," and "impact/effect/change." We completed this search by screening the reference lists of the selected articles.